The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F22%3A00082431" target="_blank" >RIV/00023001:_____/22:00082431 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/22:10440197 RIV/00216208:11110/22:10440197

Result on the web

<a href="https://link.springer.com/content/pdf/10.1007/s11883-022-00982-3.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s11883-022-00982-3.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11883-022-00982-3" target="_blank" >10.1007/s11883-022-00982-3</a>

Result language

angličtina

Original language name

The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia

Original language description

Purpose of Review To review the currently available data on the effect of Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on postprandial lipaemia. Recent Findings Out of the available studies that examined the respective lipid parameter, exenatide reduced postprandial triacyglycerol (TAG) in 4/6, apolipoprotein B-48 in 3/3, non-esterified fatty acids in 2/2, and apolipoprotein C-III and very low-density lipoprotein cholesterol (VLDL-C) in 1/1 studies. Liraglutide reduced postprandial TAG in 2/2, apolipoprotein B-48 in 3/3 and apolipoprotein C-III, chylomicron-TAG and VLDL1-TAG in 1/1 studies. Lixisenatide reduced postprandial chylomicron-TAG and apolipoprotein B-48 in 1 study. Semaglutide reduced postprandial TAG, apolipoprotein B-48 and VLDL in 1 study. Dulaglutide reduced postprandial apolipoprotein B-48 in 1 study. GLP-1 RAs have consistent beneficial effects on postprandial lipaemia with most of the data coming from studies with exenatide and liraglutide. Reduction of postprandial lipaemia might be one of the mechanisms behind the pleiotropic effects of GLP-1 RAs.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30202 - Endocrinology and metabolism (including diabetes, hormones)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Current atherosclerosis reports

ISSN

1523-3804

e-ISSN

1534-6242

Volume of the periodical

24

Issue of the periodical within the volume

1

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

9

Pages from-to

13-21

UT code for WoS article

000751991200002

EID of the result in the Scopus database

2-s2.0-85123636210